Nicotinamide Mononucleotide

Nicotinamide Mononucleotide

Best for

Raise cellular NAD+ levels

Large effect, needs confirmation · 250–3000 mg/day for 2–20 weeks · 11 studies , n=239

19 papers · 2 claims · 58 outcomes scored · 1 positive

Outcomes

What nicotinamide mononucleotide actually does, by outcome

Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.

Outcome Effect Evidence Dose Weeks Rank
Raise cellular NAD+ levels Large effect, needs confirmation
large
11 RCTs n=239 250–3000 mg 2–20 wk #1/2
Slow biological aging markers Not enough research
1 RCT n=34 250 mg 12 wk
Buy well

Recommended Nicotinamide Mononucleotide products

Real products that dose Nicotinamide Mononucleotide where the research does, in a clean formulation, from brands we've audited. We only list ones we'd stand behind.

Chosen for adequate Nicotinamide Mononucleotide dosing vs. the studied range, a clean formulation (grade A–C), and independent brand-quality audits. Not sponsored.

Risk profile

Adverse events and known drug interactions

Safety events

serious adverse event (SAE) severe
Common cold moderate
Dyslipidemia mild
High blood pressure mild
Loose stool mild
Acne vulgaris mild
mouth ulcer mild
hyperacidity mild

Drug interactions

Letrozole moderate decreases effect
Cyclophosphamide moderate decreases concentration

Sources

  1. 1. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. (2019)
  2. 2. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. (2021)
  3. 3. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults. (2022)
  4. 4. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. (2023)
  5. 5. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. (2023)
  6. 6. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. (2023)
  7. 7. Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial. (2025)
  8. 8. Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial. (2025)
  9. 9. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. (2025)
  10. 10. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. (2022)

Generated August 14, 2026

Want personalized recommendations?

Show me what works for me